Company news
Nanobiotix Sa (EURONEXT:NANO) news
Nanobiotix Sa news releases on 6ix. Latest, Oct 1, 2026: NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
Press releases & updates
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
October 1, 2026
NANOBIOTIX annonce la nomination d’Arnd Christ au poste de directeur financier
September 30, 2026
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
September 24, 2026
NANOBIOTIX fait le point sur ses activités et ses résultats financiers du premier semestre 2026
September 23, 2026
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
September 14, 2026
NANOBIOTIX annonce les résultats complets de la phase 1 pour JNJ-1900 (NBTXR3) dans le cancer du poumon non à petites cellules inopérable et récurrent
September 13, 2026
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment
September 8, 2026
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
August 24, 2026
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
July 29, 2026
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
June 2, 2026
Nanobiotix Joins the Euronext Tech Leaders Index
June 2, 2026
NANOBIOTIX Announces Closing of Global Offering
May 26, 2026
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
May 22, 2026
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
May 21, 2026
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
May 21, 2026
Nanobiotix Announces Launch of Global Follow-On Offering
May 20, 2026
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
May 17, 2026
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
May 4, 2026
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
April 20, 2026
Voting Rights and Shares Capital of the Company
April 7, 2026
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
March 31, 2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
March 30, 2026
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
March 26, 2026
NANOBIOTIX Statement Regarding Recent Media Speculation
March 25, 2026
NANOBIOTIX to Participate in Investor Conferences in March
February 25, 2026
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
December 15, 2025
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
November 24, 2025
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
November 13, 2025
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
November 11, 2025
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
November 3, 2025
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
October 31, 2025
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
October 24, 2025
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
October 1, 2025
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
September 30, 2025
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
September 29, 2025
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
September 17, 2025
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
July 7, 2025
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
May 28, 2025
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
May 21, 2025
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
May 12, 2025
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
May 5, 2025
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
April 30, 2025